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After publication of the original article [1], it came to the
authors’ attention that evidence relating to the epitopes
recognised and cross reactivities of the antibodies that
form the parents of Bapineuzumab and Solanezumab was
omitted from Table 1.
An updated version of Table 1 is published in this
erratum, with the inclusion of three new references [12–14].
This evidence do not in any way undermine the
argument that the cross-reactivities of anti-amyloid
antibodies may confound research, and in fact can be
interpreted as strengthening the argument.
The cross-reactivity of both Bapineuzumab and
Solanezumab with various Aβ C-terminals and the
cross reactivity of Solanezumab with various plasma
proteins does not clarify the understanding of the APP
proteolytic system and its role in disease, or identify
with any certainty which peptides are of interest and
are being targeted.References
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Table 1 Epitopes and cross reactivities of selected antibodies raised against Aβ
Antibody Epitope Cross Reactivity Ref
4G8 Raised against synthetic peptide Aβ17-24; epitope
lies within aa 18–23; recognises multiple forms of Aβ
Cross reacts with APP770 and P3; reacts with conformational
epitope of aggregated fibrils including α-synuclein
[2–4]
6E10 Raised against Aβ1-17; epitope lies within aa 4–9;
recognises Aβ with intact N-terminal epitope
Cross reacts with APP and Aβ(1–16); No reaction predicted
with P3
[2, 5]
6F3D Raised against synthetic peptide Aβ8-17; epitope
lies within aa 10–15; recognises Aβ with
intact N-terminal epitope
Predicted to react with Aβ(1–16); Does not react with P3 [2, 6]
MBC40
(Aβ40)
Recognises C-terminal Aβ peptides ending at aa40;
epitope not well described
Cross reacts with N-terminal truncated peptides including P3 [2]
MBC42
(Aβ42)
Recognises C-terminal Aβ peptides ending at aa42;
epitope not well described
Cross reacts with N-terminal truncated peptides including P3 [2]
BS85 Raised against Aβ(25–35); recognises Aβ38, Aβ39, Aβ40,
Aβ42 and Aβ43; epitope not well described
Cross reacts with N-terminal truncated peptides including P3 [2]
BC05 Raised against Aβ(35–43); recognises Aβ42 and Aβ43;
epitope not well described
Cross reacts with N-terminal truncated peptides including P3;
does not recognise Aβ40; used in commercial ELISA kits
for the detection of Aβ42
[7, 8]
BA27 Raised against Aβ(1–40) Recognises Aβ40; 100-1000x
more reactive with Aβ40 than Aβ42 and Aβ43; epitope
not well described
Cross reacts with N-terminal truncated peptides including P3;
used in commercial ELISA kits for the detection of Aβ40
[7]
AβN17
(Leu)
Raised against P3(40); recognises P3(40) and synthetic
P3(42) peptide; epitope not well described
Reactivity with insoluble, aggregated P3(42) not confirmed [7, 9, 10]
3D6 Raised against Aβ with N-terminal aspartic acid; epitope
lies within aa 1–5; recognises multiple C-terminal variations
Does not cross react with sAPPs or full length APP;
No reactivity with N-terminally altered Aβ; No reaction
predicted with P3; parent of Bapineuzumab
[11–13]
266 Raised against synthetic Aβ; epitope lies within aa 13–28;
recognises soluble monomer and multiple
C-terminal variations
Cross reacts with various plasma proteins containing the
core sequence KLVFF; does not cross react with P3;
parent of Solanezumab
[11–14]
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